Posted by Michael Wonder on 25 Apr 2023
bluebird bio submits biologics license application to FDA for lovotibeglogene autotemcel (lovo-cel) for patients with sickle cell disease 12 years and older with a history of vaso-occlusive events
24 April 2023 - BLA submission based on data from the largest and most mature clinical development program for any gene therapy in sickle cell disease.
bluebird bio today announced the submission of its biologics license application to the US FDA for lovotibeglogene autotemcel (lovo-cel) gene therapy in patients with sickle cell disease ages 12 and older who have a history of vaso-occlusive events.
